PIn a new study, Spanish researchers have developed a cell therapy for a type of leukemia for which there are currently few treatment options. This STAb-T cell therapy is based on STAb-TRead More…
20Jan/23
11Dec/22
Whole-Body PET Scans Reveal Complex Characterization of Immunotherapy Response in Cancer Patients
Immune checkpoint inhibitors activate the host immune system to defend against tumors, and although this cancer therapy has shown remarkable success today, the chances of patient response to the therapy are stillRead More…
18Nov/22
CAR-T Cells Targeting Tumor Macrophages Show Promise for Treating a Range of Solid Tumors
In a recent study, researchers from the Icahn School of Medicine at Mount Sinai show that a new cancer immunotherapy that uses one type of immune cell to kill another type ofRead More…
25Oct/22
T Cells Expressing Alloimmune Defense Receptor (ADR) Show Promise in Preventing Graft-Versus-Host Disease and Cancer Recurrence
In a recent study, researchers from Baylor College of Medicine and Boston Children’s Hospital, among other institutions, genetically modified T cells to control two major life-threatening complications, graft-vs-host disease (GvHD) and cancerRead More…
14Oct/22
Creative Biolabs Attended the 10th Annual Immuno-Oncology Summit as an Exhibitor
The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, attended the 10th Annual Immuno-Oncology Summit at booth #9 and has attracted many attendeesRead More…
11Aug/22
Single-cell Analysis Reveals Mechanism of Relapse of CD19-targeted CAR-T Therapy
Chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting CD19 has achieved surprising results in the treatment of malignant hematological tumors such as relapsed/refractory acute lymphoblastic leukemia (ALL). Clinical trial data show that theRead More…
01Jul/22
Synthetic IL-9 Receptor Enables T Cells to Fight Cancer without Chemotherapy or Radiation
Immunotherapy is currently a hot topic in the field of tumor treatment, and has shown excellent therapeutic effects in clinic. Among all kinds, adoptive T cell therapy is undoubtedly the most anticipated.Read More…
17Jun/22
IFN-γ Receptor Signaling Pathway Enables CAR-T Cells to Efficiently Kill Solid Tumors
In a new study, researchers from Massachusetts General Hospital find that the interferon gamma receptor (IFNγR) signaling pathway is critical for glioblastoma susceptibility to CAR-T cell immunotherapy . The same phenomenon hasRead More…
10Jun/22
CAR-T Cells Targeting CD123 Specifically Kill Acute Myeloid Leukemia Cells
In a new preclinical study, researchers from Weill Cornell Medicine found that genetically engineered T cells successfully targeted specific cancer cells that may lead to relapse in acute myeloid leukemia (AML), andRead More…
11May/22
Research Advances in CAR-T Cell Therapy (as of May 2022)
CAR-T (chimeric-antigen receptor T-cell immunotherapy) has significant efficacy in the treatment of acute leukemia and non-Hodgkin’s lymphoma, and is considered to be one of the most promising tumor treatments. In recent years,Read More…